Ryan Richardson, BioNTech chief strategy officer

BioN­Tech touts dif­fer­ences with Mod­er­na in race for can­cer vac­cines

BioN­Tech chief strat­e­gy of­fi­cer Ryan Richard­son high­light­ed the dif­fer­ences be­tween his com­pa­ny’s can­cer vac­cine and an­oth­er un­der de­vel­op­ment by Mod­er­na and Mer­ck, as the com­pa­nies race each oth­er for a piece of what could be a ma­jor new class of prod­ucts.

Richard­son spoke at an in­vest­ment con­fer­ence host­ed last week by SVB Se­cu­ri­ties and his com­ments were de­scribed in an an­a­lyst note.

BioN­Tech has sev­er­al mR­NA can­cer can­di­dates in the works, in­clud­ing for ad­vanced melanoma, ovar­i­an can­cer and non-small cell lung can­cer, ac­cord­ing to its web­site. The ri­val­ry with Mod­er­na and Mer­ck is fo­cused around its in­di­vid­u­al­ized vac­cine, RO7198457 (al­so known as BNT122), which it calls an in­di­vid­u­al­ized Neoanti­gen Spe­cif­ic im­munoTher­a­py, or iN­eST. It’s de­vel­op­ing the vac­cine with Genen­tech.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters